Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: The breast cancer health disparities study

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages

  Slattery, Martha L ^a   Herrick, Jennifer S ^a   Torres Mejia, Gabriella ^b   John, Esther M ^c,d   Giuliano, Anna R ^e   Hines, Lisa M ^f   Stern, Mariana C ^g   Baumgartner, Kathy B ^h   Presson, Angela P ^a   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Breast cancer; Cytokines; Interleukins; Mortality; Polymorphisms

Indexed keywords

INTERLEUKIN DERIVATIVE;

ADULT; AGED; BREAST NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; ETHNIC GROUP; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE DISPARITY; HUMAN; INCIDENCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; POPULATION GENETICS; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; HEALTHCARE DISPARITIES; HUMANS; INCIDENCE; INTERLEUKINS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84905715075     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu078     Document Type: Article

References (54)

1. DeNardo, D.G., et al. (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res, 9, 212.
2. Shen, W., et al. (2010) Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Neurochem Res, 35, 940-6.
3. Korantzis, I., et al. (2012) Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel. Anticancer research, 32, 4569-80.
4. Lerebours, F., et al. (2008) NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer, 8, 41.
5. Snoussi, K., et al. (2010) Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer, 10, 283.
6. Gerger, A., et al. (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat, 119, 701-5.
7. Kuhn, D.J., et al. (2005) The role of interleukin-2 receptor alpha in cancer. Front Biosci, 10, 1462-74.
8. Snoussi, K., et al. (2005) Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw, 16, 253-60.
9. Wang, L., et al. (2012) A miRNA binding site single-nucleotide polymorphism in the 3'-UTR region of the IL23R gene is associated with breast cancer. PLoS One, 7, e49823.
10. Madeleine, M.M., et al. (2011) Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat, 129, 887-99.
11. Slattery, M.L., et al. (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev, 16, 747-55.
12. Ferrari, S.L., et al. (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab, 88, 255-9.
13. Mohlig, M., et al. (2004) Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab, 89, 1885-90.
14. Slattery, M.L., et al. (2012) Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis, 33, 1512-21.
15. Slattery, M.L., et al. (2007) Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat, 102, 85-101.
16. Angeles-Llerenas, A., et al. (2010) Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control, 21, 577-86.
17. John, E.M., et al. (2003) Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev, 12, 1143-52.
18. John, E.M., et al. (2005) Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomarkers Prev, 14, 2905-13.
19. Falush, D., et al. (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics, 164, 1567-87.
20. Pritchard, J.K., et al. (2000) Inference of population structure using multilocus genotype data. Genetics, 155, 945-59.
21. Nyholt, D.R. (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American journal of human genetics, 74, 765-9.
22. Li, J., et al. (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity, 95, 221-7.
23. Yu, K., et al. (2009) Pathway analysis by adaptive combination of P-values. Genetic epidemiology, 33, 700-9.
24. Kai Yu, O.L., et al. (2011) ARTP Gene and Pathway p-values computed using the Adaptive Rank Truncated Product. pp. R package.
25. Tibshirani, T. (1996) Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society, 58, 267-288.
26. Lange, K., et al. (2001) Mendel version 4.0: A complete package for the exact genetic analysis of discrete traits in pedigree and population data sets. Americal Journal of Human Genetics, 69 (supplement), 504.
27. Kumar, S., et al. (2003) Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol, 163, 2531-41.
28. Speirs, V., et al. (1999) Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. Int J Oncol, 15, 1251-4.
29. Zapata-Tarres, M., et al. (2013) Interleukin-1 receptor antagonist gene polymorphism increases susceptibility to septic shock in children with acute lymphoblastic leukemia. Pediatr Infect Dis J, 32, 136-9.
30. Liu, X., et al. (2010) Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat, 124, 821-5.
31. Liu, J., et al. (2006) Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. Int J Cancer, 118, 2554-8.
32. Rogers, A., et al. (2007) Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies. Bone, 40, 105-10.
33. Miller, L.J., et al. (2000) Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest, 18, 293-302.
34. Garcia-Tunon, I., et al. (2004) Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res, 6, R1-7.
35. Roncarolo, M.G., et al. (1988) Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. Clin Immunol Immunopathol, 49, 53-62.
36. Zier, K.S., et al. (1984) Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes, 33, 552-5.
37. Hulme, M.A., et al. (2012) Central role for interleukin-2 in type 1 diabetes. Diabetes, 61, 14-22.
38. Torres-Mejia, G., et al. (2012) Moderate-intensity physical activity ameliorates the breast cancer risk in diabetic women. Diabetes Care, 35, 2500-2.
39. Mantovani, G., et al. (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer, 98, 84-91.
40. Salgado, R., et al. (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer, 103, 642-6.
41. Hefler, L.A., et al. (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res, 11, 5718-21.
42. Balasubramanian, S.P., et al. (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer, 6, 188.
43. Yu, K.D., et al. (2010) Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Treat, 122, 483-8.
44. DeMichele, A., et al. (2009) Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res, 69, 4184-91.
45. Kundu, N., et al. (1996) Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst, 88, 536-41.
46. Giordani, L., et al. (2003) Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem, 49, 1664-7.
47. Knechtel, G., et al. (2010) Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol, 136, 1813-9.
48. Murray, J.L., et al. (2013) Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat, 138, 917-24.
49. Wilkening, S., et al. (2008) Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis, 29, 1202-6.
50. Waugh, D.J., et al. (2008) The interleukin-8 pathway in cancer. Clin Cancer Res, 14, 6735-41.
51. Zuccari, D.A., et al. (2012) An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem, 114, 571-6.
52. Snoussi, K., et al. (2006) Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum Immunol, 67, 13-21.
53. Chen, W.C., et al. (2013) Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology, 63, 225-33.
54. Simpson, E., et al. (2013) Obesity and breast cancer: role of inflammation and aromatase. J Mol Endocrinol.